News tagged with cancer vaccine

Brazil starts HPV vaccination program

Brazilian President Dilma Rousseff on Monday said the country was rolling out a vaccination program to protect five million 11-to 13-year-old girls against the human papilloma virus (HPV), which can cause cause cervical cancer.

Mar 10, 2014
popularity not rated yet | comments 0

Hitchhiking vaccines boost immunity

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

Feb 17, 2014
popularity 5 / 5 (5) | comments 0

H. pylori vaccine shows promise in mouse studies

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and ha ...

Dec 19, 2013
popularity 5 / 5 (1) | comments 0

Cancer vaccine

The term cancer vaccine refers to a vaccine that either prevents infections with cancer-causing viruses, treats existing cancer or prevents the development of cancer in certain high risk individuals.

Some cancers, such as cervical cancer and some liver cancers, are caused by viruses, and traditional vaccines against those viruses, such as HPV vaccine and Hepatitis B vaccine, will prevent those cancers.

Scientists have also been trying to develop vaccines against existing cancers. Some researchers believe that cancer cells routinely arise and are destroyed by the healthy immune system; cancer forms when the immune system fails to destroy them. One approach to cancer vaccination is to separate proteins from cancer cells and immunize cancer patients against those proteins, in the hope of stimulating an immune reaction that would kill the cancer cells. Therapeutic cancer vaccines are being developed for the treatment of breast, lung, colon, skin, kidney, prostate, and other cancers..

On April 14 2009 Dendreon Corporation announced that their Phase III clinical trial of Provenge, a cancer vaccine designed to treat prostate cancer, had succeeded in demonstrating an increase in survival. This is the first robust, statistically significant Phase III result for a cancer vaccine, although the data have yet to be scrutinized by the U.S. Food and Drug Administration or by European Union regulatory agencies. Dendreon is forecasting marketing approval by the FDA by 2010

If Provenge is approved by the FDA, Dendreon will have opened a new era in cancer care.[citation needed]

This text uses material from Wikipedia licensed under CC BY-SA